Log in

Company updateBusinessLine

Biocon's Pebrilzo gets first EMA tailored pathway approval

Positive+40

GreyOak summary

Biocon Ltd received marketing authorisation from the European Commission for Pebrilzo, a pertuzumab biosimilar. This marks the first approval under the EMA's new tailored clinical pathway. The drug is indicated for treating HER2-positive breast cancer across multiple stages in the European Union.

What it affects

  • BioconBIOCONPositive +40

    Received EMA approval for Pebrilzo biosimilar.Rolling sentiment Positive +22

Source

Read the original at BusinessLine

More Biocon news

All Biocon news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy